



(19)

Europäische Patentamt

Europäische Patent Office

Office européen des brevets



(11)

EP 0 818 442 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
14.01.1998 Bulletin 1998/03(51) Int Cl. 6: C07C 317/44, C07C 323/60,
C07D 209/48, C07D 213/64,
A61K 31/16

(21) Application number: 97304971.1

(22) Date of filing: 08.07.1997


(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

- Rizzi, James P.
Groton, Connecticut 06340 (US)
- Rawson, David J.
Sandwich, Kent (GB)

(30) Priority: 12.07.1996 US 21652 P

(71) Applicant: PFIZER INC.
New York, N.Y. 10017 (US)(72) Inventors:
• Burgess, Laurence E.
Groton, Connecticut 06340 (US)(74) Representative: Hayles, James Richard
Pfizer Limited,
Patents Department,
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)(54) Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of
tumour necrosis factor

(57) A compound of the formula



wherein n, p, q, X, Y and Ar are as defined herein,
useful in the treatment of arthritis, cancer, tissue ulceration,
restenosis, periodontal disease, epidermolysis
bullosa, scleritis or other diseases characterized by
matrix metalloproteinase activity, as well as AIDS, sepsis,
septic shock or other diseases involving the production
of TNF.

EP 0 818 442 A2

Description

Background of the Invention

5 The present invention relates to cyclic sulfone derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.


10 This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to the pharmaceutical compositions useful therefor.

There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalloproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving 15 abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J. Leuk. Biol., 52 (2): 244-248, 1992).

Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Friers FEBS Letters, 1991, 285, 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al. Clinical Immunology and Immunopathology, 1992, 62 S11).

Summary of the Invention

25 The present invention relates to a compound of the formula




or a pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond:

40 n is 0, 1 or 2;

p is 0 or 1;

q is 0, 1 or 2;

45 X, Y and Z are each independently CR¹R² wherein R¹ and R² are each independently hydrogen, (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; (C₂-C₆)alkenyl, (C₆-C₁₀)aryl(C₂-C₆)alkenyl, (C₅-C₉)heteroaryl(C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₆-C₁₀)aryl(C₂-C₆)alkynyl, (C₅-C₉)heteroaryl(C₂-C₆)alkynyl, (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkyl (difluoromethylene), (C₁-C₃)alkyl(difluoromethylene) (C₁-C₃)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyl(hydroxymethylene), piperidyl, (C₁-C₆)alkylpiperidyl, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, R³(C₁-C₆)alkyl wherein R³ is (C₁-C₆)acylpiperazino, (C₆-C₁₀)arylpiperazino, (C₅-C₉)heteroaryl(piperazino, (C₁-C₆)alkylpiperazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpiperazino, (C₅-C₉)heteroaryl(C₁-C₆)alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)arylpiperidyl, (C₆-C₉)heteroaryl(piperidyl, (C₁-C₆)alkylpiperidyl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(piperidyl(C₁-C₆)alkyl, (C₅-C₉)heteroaryl(piperidyl(C₁-C₆)alkyl, (C₁-C₆)acylpiperidyl, or a group of the formula



5


10

wherein r is 0 to 6;

D is hydroxy, (C_1-C_6) alkoxy or NR^4R^5 wherein R^4 and R^5 are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl optionally substituted by (C_1-C_6) alkylpiperidyl, (C_6-C_{10}) arylpiperidyl, (C_5-C_9) heteroarylpiriperidyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) aryl (C_6-C_{10}) aryl or (C_3-C_6) cycloalkyl; piperidyl, (C_1-C_6) alkylpiperidyl, (C_6-C_{10}) arylpiperidyl, (C_5-C_9) heteroarylpiriperidyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) aryl (C_6-C_{10}) aryl, (C_3-C_6) cycloalkyl, $R^6(C_2-C_6)$ alkyl, (C_1-C_6) alkyl $(CHR^6)(C_1-C_6)$ alkyl wherein R^6 is hydroxy, (C_1-C_6) acycloxy, (C_1-C_6) alkoxy, piperazino, (C_1-C_6) acylamino, (C_1-C_6) alkylthio, (C_6-C_{10}) aryltio, (C_1-C_6) alkylsulfinyl, (C_1-C_6) alkylsulfoxyl, (C_6-C_{10}) arylsulfoxyl, amino, (C_1-C_6) alkylamino, $((C_1-C_6)$ alkyl) $_2$ amino, (C_1-C_6) acylpiperazino, (C_1-C_6) alkylpiperazino, (C_6-C_{10}) aryl (C_1-C_6) alkylpiperazino, (C_5-C_9) heteroaryl (C_1-C_6) alkylpiperazino, morpholino, thiomorpholino, piperidino or pyrrolidino; $R^7(C_1-C_6)$ alkyl, (C_1-C_5) alkyl $(CHR^7)(C_1-C_6)$ alkyl wherein R^7 is piperidyl or (C_1-C_6) alkylpiperidyl; and $CH(R^8)COR^9$ wherein R^8 is hydrogen, (C_1-C_6) alkyl, (C_5-C_{10}) aryl (C_1-C_6) alkyl, (C_5-C_9) heteroaryl (C_1-C_6) alkyl, (C_1-C_6) alkylthio (C_1-C_6) alkyl, (C_6-C_{10}) aryltio (C_1-C_6) alkyl, (C_1-C_6) alkylsulfinyl (C_1-C_6) alkyl, (C_5-C_{10}) aryl-sulfinyl (C_1-C_6) alkyl, (C_1-C_6) alkylsulfonyl (C_1-C_6) alkyl, (C_6-C_{10}) arylsulfonyl (C_1-C_6) alkyl, hydroxy (C_1-C_6) alkyl, amino (C_1-C_6) alkyl, (C_1-C_6) alkylamino (C_1-C_6) alkyl, $((C_1-C_6)$ alkylamino) $_2$ (C_1-C_6) alkyl, $R^{10}R^{11}NCO(C_1-C_6)$ alkyl or $R^{10}OCO(C_1-C_6)$ alkyl wherein R^{10} and R^{11} are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_6-C_{10}) aryl (C_1-C_6) alkyl and (C_5-C_9) heteroaryl (C_1-C_6) alkyl; and R^9 is $R^{12}O$ or $R^{12}R^{13}N$ wherein R^{12} and R^{13} are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_6-C_{10}) aryl (C_1-C_6) alkyl and (C_5-C_9) heteroaryl (C_1-C_6) alkyl; and Ar is (C_6-C_{10}) aryl or (C_5-C_9) heteroaryl, each of which may be optionally substituted by (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) aryl (C_2-C_6) alkenyl, (C_5-C_9) heteroaryl (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_6-C_{10}) aryl (C_2-C_6) alkynyl or (C_5-C_9) heteroaryl (C_2-C_6) alkynyl optionally substituted by (C_1-C_6) alkyl, (C_1-C_6) alkylamino, (C_1-C_6) alkylthio, (C_1-C_6) alkoxy, trifluoromethyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) arylamino, (C_6-C_{10}) aryltio, (C_6-C_{10}) aryloxy, (C_5-C_9) heteroarylarnino, (C_5-C_9) heteroarylthio, (C_5-C_9) heteroaryloxy, (C_6-C_{10}) aryl (C_6-C_{10}) aryl, (C_3-C_6) cycloalkyl, hydroxy (C_1-C_6) alkyl, (C_1-C_6) alkyl(hydroxymethylene), piperazinyl, (C_6-C_{10}) aryl (C_1-C_6) alkoxy, (C_5-C_9) heteroaryl (C_1-C_6) alkoxy, (C_1-C_6) acylamino, (C_1-C_6) acylthio, (C_1-C_6) acyloxy, (C_1-C_6) alkylsulfinyl, (C_6-C_{10}) arylsulfinyl, (C_1-C_6) alkylsulfonyl, (C_6-C_{10}) arylsulfonyl, amino, (C_1-C_6) alkylamino, $((C_1-C_6)$ alkyl) $_2$ amino or R^3 alkyl wherein R^3 is defined as above; halo, hydroxy, (C_1-C_6) alkyl or (C_1-C_6) alkoxy wherein the alkyl or alkoxy groups may be optionally substituted by (C_1-C_6) alkylamino, (C_1-C_6) alkylthio, (C_1-C_6) alkoxy, trifluoromethyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) arylarnino, (C_6-C_{10}) aryltio, (C_6-C_{10}) aryloxy, (C_5-C_9) heteroarylarnino, (C_5-C_6) heteroarylthio, (C_5-C_9) heteroaryloxy, (C_6-C_{10}) aryl (C_6-C_{10}) aryl, (C_3-C_6) cycloalkyl, hydroxy (C_1-C_6) alkyl, (C_1-C_6) alkyl(hydroxymethylene), piperazinyl, (C_6-C_{10}) aryl (C_1-C_6) alkoxy, (C_5-C_9) heteroaryl (C_1-C_6) alkoxy, (C_1-C_6) acylamino, (C_1-C_8) acylthio, (C_1-C_6) acyloxy, (C_1-C_6) alkylsulfinyl, (C_6-C_{10}) arylsulfinyl, (C_1-C_6) alkylsulfonyl, (C_6-C_{10}) arylsulfonyl, amino, (C_1-C_6) alkylamino or $((C_1-C_6)$ alkyl) $_2$ amino; (C_2-C_6) alkenyl, (C_6-C_{10}) aryl (C_2-C_6) alkenyl, (C_6-C_9) heteroaryl (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_6-C_{10}) aryl (C_2-C_6) alkynyl, (C_5-C_9) heteroaryl (C_2-C_6) alkynyl, (C_1-C_6) alkylamino, (C_1-C_6) alkylthio, (C_1-C_6) alkoxy, trifluoromethyl, (C_1-C_6) alkyl (difluoromethylene), (C_1-C_3) alkyl(difluoromethylene) (C_1-C_3) alkyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) arylarnino, (C_6-C_{10}) aryltio, (C_6-C_{10}) aryloxy, (C_5-C_9) heteroarylarnino, (C_5-C_9) heteroaryloxy, (C_3-C_6) cycloalkyl, (C_1-C_6) alkyl(hydroxymethylene), piperidyl, (C_1-C_6) alkylpiperidyl, (C_1-C_6) acylamino, (C_1-C_6) acylthio, (C_1-C_6) acyloxy, $R^3(C_1-C_6)$ alkyl or $R^3(C_1-C_6)$ alkoxy wherein R^3 is (C_1-C_6) acylpiperazino, (C_6-C_{10}) arylpiperazino, (C_5-C_9) heteroaryl (C_1-C_6) alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl, (C_1-C_6) alkylpiperidyl, (C_6-C_{10}) arylpiperidyl, (C_5-C_9) heteroaryl (C_1-C_6) alkyl, (C_1-C_6) acylpiperidyl, or a group of the formula

55

5



10

wherein r and D are as defined above;

with the proviso that when q is 1 and X and Y are both CR¹R² wherein one of either R¹ or R² must be hydrogen, p must be 1;
 15 with the proviso that when q is 0, the compound of formula I is not bicyclic; and
 with the proviso that when the broken line of formula I represents a double bond, R² does not exist.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

20 The term "alkoxy", as used herein, includes alkyl-O groups wherein "alkyl" is defined above.

The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluoro, chloro, cyano, nitro, trifluoromethyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.

25 The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents independently selected from the group consisting of fluoro, chloro, trifluoromethyl, (C₁-C₆)alkoxy, (C₆-C₁₀)aryloxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.

30 The term "acyl", as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkyloxy and the terms "alkyl" or "aryl" are as defined above.

35 The term "acyloxy", as used herein, includes acyl-O groups wherein "acyl" is defined above.

Preferred compounds of formula I include those wherein q is 0 or 2.

Other preferred compounds of formula I include those wherein q is 0 or 1

Other preferred compounds of formula I include those wherein n is 2

Other preferred compounds of formula I include those wherein X and Y are both CR¹R² wherein R¹ and R² are hydrogen.

40 Other preferred compounds of formula I include those wherein Ar is methoxyphenyl, phenoxyphenyl, benzoxyphenyl or halophenyl

More preferred compounds of formula I include those wherein q is 0, p is 1, m is 2, X and Y are CR¹R² are hydrogen and Ar is methoxyphenyl, phenoxyphenyl or benzoxyphenyl.

45 More preferred compounds of formula I include those wherein q is 0, p is 0, m is 2, X and Y are CR¹R² are hydrogen and Ar is methoxyphenyl, phenoxyphenyl or benzoxyphenyl.

The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof, effective in such treatments or inhibition and a pharmaceutically acceptable carrier.

55 The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of

tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof, effective in treating such a condition.

Detailed Description of the Invention

5

The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated p, q, X, Y, Z and Ar in the reaction Schemes and the discussion that follow are defined as above.

10

15

20

25

30

35


40


45

50


55

SCHEME 1




SCHEME 2

SCHEME 3



SCHEME 3 (Continued)

5



10

15

XIV


20

6

25

30

35



XIII


40

45


50

55

SCHEME 4



SCHEME 5



55 In reaction 1 of Scheme 1, the aryl sulfonyl chloride compound of formula **VII** is converted to the corresponding sodium aryl sulfinate compound of formula **VI** by reacting **VII** with sodium iodine in the presence of a polar aprotic solvent, such as acetone, under inert atmosphere. The reaction mixture is stirred, at room temperature, for a time period between about 12 hours to about 18 hours, preferably about 15 hours.



In reaction 2 of Scheme 1, the compound of formula **VI** is converted to the corresponding 2-iodo-3-(aryl) sulfonyl propionic acid compound of formula **V** by reacting **VI** with acrylic acid and iodine in the presence of a polar aprotic

solvent, such as methylene chloride. The reaction mixture is stirred under inert atmosphere, at room temperature, for a time period between about 2.5 days to about 3.5 days, preferably about 3 days.

In reaction 3 of Scheme 1, the compound of formula **V** is converted to the corresponding (E)-3-(aryl)sulfonyl-prop-2-enoic acid compound of formula **IV** by treating **V** with a base, such as triethylamine, under inert atmosphere. The reaction is stirred, at room temperature, for a time period between about 10 hours to about 14 hours, preferably about 12 hours

In reaction 4 of Scheme 1, the compound of formula **IV** is converted to the corresponding carboxylic acid compound of formula **III** by heating **IV** with an excess amount of a compound of the formula

wherein q is 1 and p is 1, or an excess amount of the diene compound of the formula



wherein q is 0 and p is 1, to reflux in the presence of a polar aprotic solvent, such as toluene, for a time period between about 40 hours to about 56 hours, preferably about 48 hours.

In reaction 5 of Scheme 1, the compound of formula **III** is converted to the corresponding N-(benzyloxy)-carboxamide compound of formula **III** by reacting **II** with benzylhydroxylaminehydrochloride, dimethylaminopyridine and dicyclohexylcarbodiimide in the presence of a polar aprotic solvent, such as methylene chloride, under inert atmosphere

The reaction mixture is stirred, at room temperature, for a time period between about 15 hours to about 25 hours, preferably about 20 hours.

In reaction 6 of Scheme 1, the compound of formula **II** is converted to the corresponding hydroxamic acid compound of formula **I** by treating **II** with hydrogen in the presence of a catalyst, such as 5% palladium on barium sulfate, and a polar aprotic solvent, such as methanol. The reaction mixture is stirred for a time period between about 2 hours to about 4 hours, preferably about 3 hours.

In reaction 1 of Scheme 2, the cycloalkenecarboxylate compound of formula **XII**, wherein p is 0 or 1 and X is CH₂, is converted to the corresponding arylthiocycloalkanecarboxylate compound of formula **XI** by adding a solution of **XII** in a polar aprotic solvent, such as tetrahydrofuran, to a solution of an arylthio compound of the formula ArSH and a base, such as butyl lithium, in a polar aprotic solvent, such as tetrahydrofuran, under inert atmosphere, at a temperature between about -75°C to about -85°C, preferable about -78°C. The reaction mixture is allowed to warm to ambient temperature over a time period between about 10 hours to about 14 hours, preferably about 12 hours.

In reaction 2 of Scheme 2, the compound of formula **XI** is oxidized to the corresponding sulfone compound of formula **X** by treating **XI** with a suitable oxidant, such as a catalytic amount of osmium tetroxide, and a reoxidant, such as N-methylmorpholine oxide, in a polar protic solvent, such as isopropanol. The reaction is carried out in a polar protic solvent, such as isopropanol, for a time period between about 4 hours to about 24 hours, preferably about 12 hours.

In reaction 3 of Scheme 2, the compound of formula **X** is converted to the corresponding carboxylic acid compound of formula **IX** by cleaving the ester moiety of **X** by either hydrolysis using a suitable base, such as sodium hydroxide, in a polar solvent, such as aqueous tetrahydrofuran, or hydrogenolysis using hydrogen in the presence of a polar solvent, such as methanol, and a catalyst, such as 10% palladium on carbon, under a pressure between about 40 psi to about 60 psi, preferably about 50 psi. The reaction is stirred for a time period between about 2 hours to about 12 hours, preferably about 8 hours.

In reaction 4 of Scheme 2, the carboxylic acid compound of formula **IX** is converted to the corresponding hydroxamic acid compound of formula **VIII** by treating **II** with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenzotriazole in a polar solvent, such as dimethylformamide, followed by the addition of hydroxylamine to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated *in situ* from a salt form, such as hydroxylamine hydrochloride, in the presence of a base, such as N-methylmorpholine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxyl group

is protected as a tert-butyl, benzyl or allyl ether, may be used in the presence of (benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate and a base, such as N-methylmorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. N,O-bis(4-methoxybenzyl)hydroxylamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesulfonic acid and trifluoroacetic acid.

5 In reaction 1 of Scheme 3, the compound of formula **XIX**, wherein p is 0 or 1, X is CH₂ and R¹⁶ is a protecting group, such as benzyl, is converted to corresponding compound of formula **XVIII**, by reacting **XIX** with a 4-tert-butyl-10 imethylsilylarylthio compound, according to the procedure described above in reaction 1 of Scheme 2.

10 In reaction 2 of Scheme 3, the compound of formula **XVIII** is converted to the corresponding compound of formula **XVII** by the addition of aqueous hydrofluoric acid to a solution of **XVIII** in a polar aprotic solvent, such as acetonitrile. The reaction mixture is stirred, at room temperature, for a time period between about 2 hours to about 5 hours, preferably about 4 hours.

15 In reaction 3 of Scheme 3, the compound of formula **XVII** is converted to the corresponding compound of formula **XVI**, wherein R¹⁴ is hydrogen or (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy (C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)aryl(sulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)aryl(sulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; or R³alkyl where R³ is defined as above, by stirring **XVII** and suitable primary or secondary alcohol in a polar aprotic solvent, such as tetrahydrofuran, under inert atmosphere. A azidodicarboxylate, such as diethylazidodicarboxylate, and a trialkyl or triarylphosphine, such as triphenylphosphine, are added and the resulting reaction mixture is stirred for a time period between about 10 hours to about 25 14 hours, preferably about 12 hours.

In reaction 4 of Scheme 3, the compound of formula **XVI** is oxidized to the corresponding sulfone compound of formula **XV** according to the procedure described above in reaction 2 of Scheme 2.

In reaction 5 of Scheme 3, the compound of formula **XV** is converted to the carboxylic acid compound of formula **XIV** according to the procedure described in reaction 3 of Scheme 2.

30 In reaction 6 of Scheme 3, the compound of formula **XVI** is converted to the corresponding hydroxamic acid compound of formula **XIII** according to the procedure described above in reaction 4 of Scheme 2.

In reaction 1 of Scheme 4, the compound of formula **XXIV**, wherein p is 0 or 1, X is CH₂ and R¹⁶ is a protecting group, such as benzyl, is converted to the corresponding compound of formula **XXIII** by reacting **XXIV** with a 4-halothiophenol, such as 4-bromothiophenol, according to the procedure described above in reaction 1 of Scheme 2.

35 In reaction 2 of Scheme 4, the compound of formula **XXIII** is converted to the corresponding compound of formula **XXII** according to procedures described above in reaction 4 of Scheme 3.

In reaction 3 of Scheme 4, the compound of formula **XXII** is converted to the corresponding compound of formula **XXI**, wherein R¹⁵ is hydrogen, (C₆-C₁₀)aryl(C₂-C₆)alkenyl, (C₅-C₉)heteroaryl(C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₆-C₁₀)aryl(C₂-C₆)alkynyl, (C₆-C₉)heteroaryl(C₂-C₆)alkynyl, (C₆-C₁₀)aryl or (C₅-C₉)heteroaryl optionally substituted by (C₁-C₆)alkyl, (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)aryl(sulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)aryl(sulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; or R³alkyl where R³ is defined as above. Coupling partners could be aryl or heteroaryl boronic acids, aryl or heteroaryl stannanes or vinyl compounds.

40 In reaction 4 of Scheme 4, the compound of formula **XXI** is converted to the corresponding compound of formula **XX** according to the procedure described above in reaction 3 of Scheme 2.

In reaction 5 of Scheme 4, the compound of formula **XX** is converted to the corresponding compound of formula **XIX** according to the procedure described above in reaction 4 of Scheme 2.

45 In reaction 1 of Scheme 5, the compound of formula **XXVIII**, wherein p is 0 or 1, X is CH₂ and R¹⁶ is a protecting group, such as benzyl, is converted to the corresponding compound of formula **XXVII** according to the procedure described above in reaction 3 of Scheme 2.

In reaction 2 of Scheme 5, the compound of formula **XXVII** is converted to the corresponding compound of formula **XXVI** according to the procedure described above in reaction 4 of Scheme 2.

50 In reaction 3 of Scheme 5, the thioether compound of formula **XXVI** is oxidized to the corresponding sulfoxide compound of formula **XXV** using a suitable oxidising agent, such as m-chloroperbenzoic acid, in a polar aprotic solvent, such as dichloromethane, at a temperature between about -10°C to about 10°C, preferably about 0°C, for a period of

time between about 30 minutes to about 4 hours, preferably about 2 hours.

Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methylammonium salts

Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.

The ability of the compounds of formula I or their pharmaceutically acceptable salts (hereinafter also referred to as the compounds of the present invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests.

Biological Assay

Inhibition of Human Collagenase (MMP-1)

Human recombinant collagenase is activated with trypsin using the following ratio: 10 µg trypsin per 100 µg of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 µg/10 µg trypsin) of soybean trypsin inhibitor is added.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:

10 mM -----> 120 µM -----> 12 µM -----> 1.2 µM -----> 0.12 µM

Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.

Collagenase is diluted to 400 ng/ml and 25 µl is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.

Substrate (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 µM in assay buffer. The assay is initiated by the addition of 50 µl substrate per well of the microfluor plate to give a final concentration of 10 µM.

Fluorescence readings (360 nm excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals.

The assay is conducted at room temperature with a typical assay time of 3 hours.

Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC₅₀ values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control inhibitor fluorescence divided by fluorescence of collagenase alone × 100) IC₅₀'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control.

If IC₅₀'s are reported to be <0.03 µM then the inhibitors are assayed at concentrations of 0.3 µM, 0.03 µM, 0.03 µM and 0.003 µM.

Inhibition of Gelatinase (MMP-2)

Inhibition of gelatinase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂ substrate (10 µM) under the same conditions as inhibition of human collagenase (MMP-1).

72kD gelatinase is activated with 1 mM APMA (p-aminophenyl mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of 30 µM, 3 µM, 0.3 µM and 0.03 µM. Each concentration is done in triplicate.

Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours

IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 µM, then the inhibitors are assayed at final concentrations of 0.3 µM, 0.03 µM, 0.003 µM and 0.003 µM.

Inhibition of Stromelysin Activity (MMP-3)

5 Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., Spectrophotometric Assay for Vertebrate Collagenase, *Anal. Biochem.* **147**, 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-Gly-SCH(CH₂CH(CH₃)₂)CO-Leu-Gly-OC₂H₅] yields a mercaptan fragment that can be monitored in the presence of Ellman's reagent.

10 Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μ l of a 10 mg/ml trypsin stock per 26 μ g of stromelysin. The trypsin and stromelysin are incubated at 37°C for 15 minutes followed by 10 μ l of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C to quench trypsin activity.

15 Assays are conducted in a total volume of 250 μ l of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter plates. Activated stromelysin is diluted in assay buffer to 25 μ g/ml. Ellman's reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μ l per well yielding at 1 mM final concentration.

20 10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μ L to the appropriate wells yields final concentrations of 3 μ M, 0.3 μ M, 0.003 μ M, and 0.0003 μ M. All conditions are completed in triplicate.

25 A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μ l to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.

30 IC₅₀ values were determined in the same manner as for collagenase.

Inhibition of MMP-13

35 Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5mM calcium chloride, 20 μ M zinc chloride, 0.02% brij). Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.

40 10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μ M, 3 μ M, 0.3 μ M, and 0.03 μ M.

45 Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is prepared as for inhibition of human collagenase (MMP-1) and 50 μ l is added to each well to give a final assay concentration of 10 μ M. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.

50 Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.

IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 μ M, inhibitors are then assayed at final concentrations of 0.3 μ M, 0.03 μ M, 0.003 μ M and 0.0003 μ M.

Inhibition of TNF Production

55 The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following *in vitro* assay:

60 Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 10⁶/ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.

65 180 μ l of the cell suspension was aliquoted into flat bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 200 μ l. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO₂ incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNF α using the R&D ELISA Kit.

70 For administration to humans for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor, a variety of conventional routes may be used including orally, parenterally and topically. In general, the active compound will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any

event, determine the appropriate dose for the individual subject.

The compounds of the present invention can be administered in a wide variety of different dosage forms, in general, the compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

5 For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonat , dicalcium phosphate and glycin may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar 10 type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

15 For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered 20 isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Additionally, it is possible to administer the compounds of the present invention topically, e.g., when treating inflammatory conditions of the skin and this may be done by way of creams, jellies, gels, pastes, and ointments, in accordance with standard pharmaceutical practice.

25 The present invention is illustrated by the following examples, but is not limited to the details thereof.

EXAMPLE 1

N-Hydroxy-3-(4-phenoxy-benzenesulfonyl)-bicyclo[2.2.2]octane-2-carboxamide

30 A mixture of O-benzyl hydroxamate (0.17 grams; 0.36 mmol) and 5% palladium or barium sulfate (0.30 grams) in methanol (50 mL) was placed under an atmosphere of hydrogen (40 psi) and shaken vigorously for 3 hours. The reaction mixture was then filtered and concentrated in vacuo to provide a glassy solid (0.15g). Purification via flash chromatography (30:70:2.5:0.5 of ethyl acetate:hexanes:acetic acid:methanol) on silica gel produced the pure hydroxamic acid as an off-white foamy solid (96 mg; 60%). M.P. 89.9-91.8°C; ¹H NMR (250 MHz, D₄-MeOH) δ 7.80 (d, 2H, J=8.6 Hz), 7.43 (t, 2H, J = 7.6 Hz), 7.23 (t, 1H, J = 7.3 Hz), 7.11 (t, 4H, J = 9.1 Hz), 3.88 (d, 1H, J= 7.7 Hz), 2.84 (d, 1H, J = 7.2 Hz), 2.18 (br s, 2H), 1.80-1.40 (m, 4H); ¹³C NMR (75.5 MHz, D₄-MeOH) δ 21.5, 25.9, 26.6, 27.4, 32.3, 42.4, 63.6, 118.8, 121.5, 126.2, 131.3, 132.0, 133.1, 156.6, 164.1, 171.8; IR (drifts): 3303-3230, 2943, 2870, 1665, 1582, 1488, 1247, 1143 cm⁻¹. HRMS: calculated for C₂₁H₂₄NO₅ 402.1375; Found 402.1352.

EXAMPLE 2

3-(4-phenoxy-benzenesulfonyl)-bicyclo[2.2.2]oct-5-ene-2-carboxylic acid

45 A stirred solution of vinyl sulfone-carboxylate (0.34 grams; 1.1 mmol) and 1,3-cyclohexadiene (5-mL, excess) in dry toluene (10 mL) was heated to reflux (120°C) for 48 hours. The reaction was concentrated in vacuo to give a blue-green oil (0.73 grams) which was purified via flash chromatography (20% ethyl acetate, 2% acetic acid, 2% methanol in hexanes on silica gel) to give the bicyclic sulfone as a light yellow oil (0.24 grams; 56%). Major Diastereomer: ¹H NMR (250 MHz, CDCl₃) δ 7.85-7.74 (m, 2H), 7.44-7.37 (m, 2H), 7.22 (c, 1H), 7.10-7.01 (m, 4H), 6.30 (t, 1H, J = 6.9 Hz), 6.11 (t, 1H, J = 6.9 Hz), 3.13 (d, 1H, J = 4.9 Hz), 2.89 (dd, 1H, J = 5.8, 2.1 Hz), 2.63-2.57 (m, 2H), 1.90-1.16 (m, 4H). LRMS: 385 (M + 1), 402 (M + 18).

EXAMPLE 3

N-Hydroxy-2-(4-methoxybenzenesulfonyl)-cyclohexane-1-carboxamid

55 N-Butyl lithium (0.56ml of a 2.5M solution in hexanes) was added to a stirred solution of 4-methoxythiophenol (1.94 grams, 13.9 mmol) in tetrahydrofuran (40ml) at -78°C under a nitrogen atmosphere. After 1 hour a solution of benzyl

1-cyclohexene-1-carboxylate (6 grams, 27.8 mmol) in tetrahydrofuran (5 ml) was added by cannula and the reaction mixture was allowed to warm to room temperature over 12 hours. The reaction was quenched with saturated sodium chloride solution and diluted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and concentrated. The crude mixture was purified by silica gel chromatography (elution with 98% hexane/2% ethyl acetate) to provide benzyl-2-(4-methoxybenzenothio)-1-cyclohexane-1-carboxylate.

Osmium tetroxide (1.85ml of a 2.5% solution in 2-methyl-2-propanol) was added to a stirred solution of benzyl-2-(4-methoxybenzenothio)-1-cyclohexane-1-carboxylate (3.3 grams, 9.27 mmol) and 4-methylmorpholine N-oxide (2.71 grams, 23.2 mmol) in aqueous acetone (40ml water/80ml acetone) at room temperature. After 2 hours the solvent was removed *in vacuo* and the residue was partitioned between dilute hydrochloric acid and ethyl acetate. The ethyl acetate layer was washed with brine, dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 90% hexane/10% ethyl acetate) to provide benzyl-2-(4-methoxybenzenesulfonyl)-1-cyclohexane-1-carboxylate.

Benzyl-2-(4-methoxybenzenesulfonyl)-1-cyclohexane-1-carboxylate (3.1 grams, 8.0 mmol) was dissolved in 300ml ethyl alcohol. 10% Palladium on carbon (0.3 grams) was added and the reaction mixture was heated at 60°C under a pressure of 50psi hydrogen for 12 hours. The mixture was cooled, the catalyst removed by filtration and the solvent concentrated. The crude mixture was purified by silica gel chromatography (elution with 95% dichloromethane/5% methanol) to provide 2-(4-methoxybenzenothio)-1-cyclohexane-1-carboxylate.

1-Hydroxybenztriazole (0.49 grams, 3.6 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.69 grams, 3.6 mmol) were added to a stirred solution of 2-(4-methoxybenzenesulfonyl)-1-cyclohexane-1-carboxylate (0.9 grams, 2.0 mmol) in dimethylformamide (20ml) at room temperature. After 30 minutes hydroxylamine hydrochloride (0.83 grams, 12.0 mmol) and triethylamine (1.83 grams, 18.1 mmol) were added and the mixture was stirred for 12 hours. The reaction mixture was diluted with ethyl acetate and washed with sodium bicarbonate solution. The organic layer was washed with 2M hydrochloric acid, then brine and dried (sodium sulfate) before concentrating. The product was purified by recrystallization (ethyl acetate/methanol) to give N-hydroxy-2-(4-methoxybenzenesulfonyl)-cyclohexane-1-carboxamide as a crystalline solid. The relative stereochemistry of the two substituents at the ring junction was shown to be *cis* by X-ray crystallography Mass spectrum (thermospray): m/z 331.1 (MNH₄⁺). ¹H NMR (CDCl₃, 400MHz, ppm) δ 9.00 (s, 1H), 7.80 (d, 2H), 7.05 (d, 1H), 3.90 (s, 3H), 3.15 (dt, 1H), 3.10 (m, 1H), 2.20-1.85 (m, 4H), 1.80-1.20 (m, 6H). Analysis found: C, 53.69; H, 6.15; N, 4.37 C₁₄H₁₉NSO₆ requires C, 53.66; H, 6.11; N, 4.47.

EXAMPLE 4

N-Hydroxy-2-(4-(2-N-phthalimido)ethoxy-benzenesulfonyl)-cyclohexane-1-carboxamide

N-Butyl lithium (1.5ml a 2.5M solution in hexanes) was added to a stirred solution of 4-t-butyldimethylsilyloxythiophenol (4.8 grams, 61.7 mmol) in tetrahydrofuran (300ml) at -78°C under a nitrogen atmosphere. After 1 hour a solution of benzyl-1-cyclohexene-1-carboxylate (8 grams, 37 mmol) in tetrahydrofuran (15 ml) was added by cannula and the reaction mixture was allowed to warm to room temperature over 12 hours. The reaction was quenched with saturated sodium chloride solution and diluted with ethyl acetate. The organic layer was separated, dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 98% hexane/2% ethyl acetate) to provide benzyl-2-(4-t-butyldimethylsilyloxybenzenothio)-1-cyclohexane-1-carboxylate.

Hydrofluoric acid (5ml of a 40% aqueous solution) was added to a stirred solution of benzyl-2-(4-t-butyldimethylsilyloxybenzenothio)-1-cyclohexane-1-carboxylate (5 grams, 11.3 mmol) in acetonitrile (50ml) at room temperature. After 12 hours the reaction mixture was poured into aqueous ammonium chloride and extracted with dichloromethane. The organics were dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 97% dichloromethane/3% methanol) to provide benzyl-2-(4-hydroxybenzenothio)-1-cyclohexane-1-carboxylate.

Benzyl-2-(4-hydroxybenzenothio)-1-cyclohexane-1-carboxylate (1 gram, 2.92 mmol) and N-(2-hydroxyethyl) phthalimide (0.56 grams, 292 mmol) were dissolved in tetrahydrofuran (30ml) and stirred at 0°C under a nitrogen atmosphere. Triphenylphosphine (0.84 grams, 3.22 mmol) and diethylazidocarboxylate (0.61 grams, 3.51 mmol) were then added and the solution was stirred for 12 hours at 50°C. The mixture was concentrated and the residue partitioned between ethyl acetate and water. The organic layer was dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 99% dichloromethane/1% methanol) to provide benzyl-2-(4-(2-N-phthalimido)ethoxybenzenothio)-1-cyclohexane-1-carboxylate.

Osmium tetroxide (0.38ml of a 2.5% solution in 2-methyl-2-propanol) was added to a stirred solution of benzyl-2-(4-(2-N-phthalimido)ethoxybenzenothio)-1-cyclohexane-1-carboxylate (0.98 grams, 1.91 mmol) and 4-methylmorpholine N-oxide (0.56 grams, 4.77 mmol) in aqueous acetone (7ml water/14ml acetone) at room temperature. After 12 hours the solvent was removed *in vacuo* and the residue was partitioned between dilute hydrochloric acid and ethyl

acetate. The ethyl acetate layer was washed with brine, dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 99% dichloromethane/1% methanol) to provide benzyl-2-(4-(2-N-phthalimido)ethoxy-benzenesulfonyl)-1-cyclohexane-1-carboxylate.

Benzyl-2-(4-(2-N-phthalimido)ethoxy-benzenesulfonyl)-1-cyclohexane-1-carboxylate (0.54 grams, 1.0 mmol) was dissolved in 60ml ethyl alcohol. 10% Palladium on carbon (60mg) was added and the reaction mixture was heated at 60°C under a pressure of 50psi hydrogen for 12 hours. The mixture was cooled, the catalyst removed by filtration and the solvent concentrated. The crude mixture was purified by silica gel chromatography (elution with 98% dichloromethane/2% methanol) to provide 2-(4-(2-N-phthalimido)ethoxy-benzenesulfonyl)-1-cyclohexane-1-carboxylate

1-Hydroxybenztriazole (78 mg, 0.58 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.11 grams, 0.58 mmol) were added to a stirred solution of 2-(4-(2-N-phthalimido)ethoxy-benzenesulfonyl)-1-cyclohexane-1-carboxylate (0.22 grams, 0.48 mmol) in dimethylformamide (5ml) at room temperature. After 30 minutes hydroxylamine hydrochloride (0.13 grams, 1.92 mmol) and triethylamine (0.29 grams, 2.89 mmol) were added and the mixture was stirred for 12 hours. The reaction mixture was diluted with ethyl acetate and washed with sodium bicarbonate solution. The organic layer was washed with 2M hydrochloric acid, then brine and dried (sodium sulfate) before concentrating. The product was purified by silica gel chromatography (elution with 98% dichloromethane/2% methanol) to provide N-hydroxy-2-(4-(2-N-phthalimido)ethoxy-benzenesulfonyl)-cyclohexane-1-carboxamide. Mass spectrum (thermospray): m/z 473 (MH⁺). ¹H NMR (CDCl₃, 400MHz, ppm) δ 7.90-7.80 (m, 4H), 7.75 (d, 2H), 7.10 (d, 2H), 4.40 (t, 2H), 4.10 (t, 2H), 2.80 (m, 1H), 2.40 (dt, 1H), 1.90-1.20 (m, 8H). Analysis found: C, 57.85; H, 5.30; N, 5.94. C₂₃H₂₄N₂SO₇. H₂O requires C, 57.37; H, 5.23; N, 5.82.

The title compounds of Example 5-6 were prepared by a method analogous to that described in Example 4.

EXAMPLE 5

N-Hydroxy-2-4-(benzyloxy)benzenesulfonyl)-cyclohexane-1-carboxamide

Mass spectrum (thermospray): m/z 407.1 (MNH₄⁺). ¹H NMR (CDCl₃, 400 MHz, ppm) δ 7.80 (d, 2H), 7.50-7.30 (m, 5H), 7.20 (d, 2H), 5.20 (d, 2H), 2.80 (m, 1H), 2.40 (dt, 1H), 1.90-1.30 (m, 8H). Analysis found: C, 59.90; H, 5.83; N, 3.08. C₂₀H₂₃NSO₅. 0.5H₂O requires C, 60.28; H, 6.07; N, 3.52.

EXAMPLE 6

N-Hydroxy-2-4-(4-methoxyphenpropyloxy)benzenesulfonyl)-cyclohexane-1-carboxamide

Mass spectrum (thermospray): m/z 449.2 (MH⁺). ¹H NMR (CDCl₃, 400MHz, ppm) δ 9.30 (1H, br s), 7.75 (2H, d),

7.10 (d, 2H), 7.00 (d, 2H), 6.85 (d, 2H), 4.60 (d, 1H), 4.00 (t, 2H), 3.85 (m, 1H), 3.80 (s, 3H), 3.10 (dt, 1H), 2.75 (t, 3H), 2.25 (d, 1H), 2.10 (m, 2H), 1.70-1.10 (m, 8H).

EXAMPLE 7

N-Hydroxy-2-4-2-methoxy-5-pyridyl)-benzenesulfonyl)-cyclohexane-1-carboxamide

N-Butyl lithium (0.92ml of a 2.5M solution in hexanes) was added to a stirred solution of 4-bromothiophenol (4.37 grams, 23 mmol) in tetrahydrofuran (30ml) at -78°C under a nitrogen atmosphere. After 1 hour a solution of benzyl 1-cyclohexene-1-carboxylate (5 grams, 23 mmol) in tetrahydrofuran (10ml) was added by cannula and the reaction mixture was allowed to warm to room temperature over 12 hours. The reaction was quenched with saturated sodium chloride solution and diluted with ethyl acetate. The organic layer was separated, dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 95% hexane/5% ethyl acetate) to provide benzyl-2-(4-bromobenzenthio)-1-cyclohexane-1-carboxylate.

Osmium tetroxide (1.53ml of a 2.5% solution in 2-methyl-2-propanol) was added to a stirred solution of benzyl-2-(4-bromobenzenthio)-1-cyclohexane-1-carboxylate (3.1 grams, 7.65 mmol) and 4-methylmorpholine N-oxide (2.24 grams, 19 mmol) in aqueous acetone (15 ml water/30ml acetone) at room temperature. After 12 hours the solvent was removed in vacuo and the residue was partitioned between dilute hydrochloric acid and ethyl acetate. The ethyl acetate layer was washed with brine, dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with dichloromethane) to provide benzyl-2-(4-bromobenzenthio)-1-cyclohexane-1-carboxylate.

Tetrakis-(triphenylphosphine)palladium (65mg, 0.057 mmol) was added to a stirred solution of 2-methoxypyridyl-5-boronic acid (460mg, 2.4 mmol) and benzyl-2-(4-bromobenzenthio)-1-cyclohexane-1-carboxylate (712mg, 1.6 mmol) in a mixture of toluene (9 ml), ethanol (5ml) and saturated sodium bicarbonate solution (4 ml). The mixture was

refluxed for 3 hours after which time the organic solvent was removed by evaporation. The residue was extracted with ethyl acetate and the organics were washed with water and saturated sodium chloride solution. The organics were dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 99% dichloromethane/1% methanol) to provide benzyl-2-(4-(2-methoxy-5-pyridyl)-benzenesulfonyl)-1-cyclohexane-1-carboxylate.

Benzyl-2-(4-(2-methoxy-5-pyridyl)-benzenesulfonyl)-1-cyclohexane-1-carboxylate (230 mg, 0.49 mmol) was dissolved in 20ml ethanol. 10% Palladium on carbon (30 mg) was added and the reaction mixture was heated at 60°C under a pressure of 50psi hydrogen for 12 hours. The mixture was cooled, the catalyst removed by filtration and the solvent concentrated. The crude mixture was purified by silica gel chromatography (elution with 95% dichloromethane/5% methanol) to provide 2-(4-(5-(2-methoxypyridyl)benzenesulfonyl)-1-cyclohexane-1-carboxylate.

1-Hydroxybenztriazole (80 mg, 0.6 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (143 mg, 0.7 mmol) were added to a stirred solution of 2-(4-(2-methoxy-5-pyridyl)-benzenesulfonyl)-1-cyclohexane-1-carboxylate (200 mg, 0.5 mmol) in dichloromethane (8 ml) at room temperature. After 30 minutes tert-butyldimethylsilylhydroxylamine (157mg, 1 mmol) and 4-methylmorpholine (0,14ml, 1 mmol) were added and the mixture was stirred for 12 hours. The solvent was removed and the reaction mixture was stirred for 2 hours in methanol/water (10ml/4 ml). The reaction mixture was concentrated and the crude mixture was purified by silica gel chromatography (elution with 98% dichloromethane/2% methanol) to provide N-hydroxy-2-(4-(2-methoxy-5-pyridyl)benzenesulfonyl)-cyclohexane-1-carboxamide. Mass spectrum (thermospray): m/Z 391 (MH⁺), 408 (MNH₄⁺). ¹H NMR (CDCl₃, 400MHz, ppm) δ 8.40 (s, 1H), 7.90 (d, 2H), 7.80 (d, 1H), 7.65 (d, 2H), 6.80 (d, 1H), 4.00 (s, 3H), 3.20 (m, 1H), 3.05 (m, 1H), 2.30-1.20 (m, 8H).

20

EXAMPLE 8

N-Hydroxy-2-(4-bromobenzenesulfoxy)-cyclohexane-1-carboxamide

N-Butyl lithium (2.86 ml of a 2.5M solution in hexanes) was added to a stirred solution of 4-bromothiophenol (14.8 grams, 78.5 mmol) in (300ml) at -78°C under a nitrogen atmosphere. After 1 hour a solution of methyl 1-cyclohexene-1-carboxylate (10 grams, 71.4 mmol) in tetrahydrofuran (20 ml) was added by cannula and the reaction mixture was allowed to warm to room temperature over 12 hours. The reaction was quenched with saturated sodium chloride solution and diluted with ethyl acetate. The organic layer was separated, dried (sodium sulfate) and concentrated. The crude mixture was dissolved in dioxane (250 ml) and water (80ml) and 2M sodium hydroxide solution (100 ml) was added. The mixture was stirred for 12 hours and then the pH was adjusted to pH 1-3 with concentrated hydrochloric acid. The dioxane was removed by evaporation and the product was extracted into dichloromethane. The organic layer was dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 30% ethyl acetate/70% hexane) to provide 2-(4-bromobenzenethio)-1-cyclohexane-1-carboxylate (contaminated with cyclohexene-1-carboxylate).

1-Hydroxybenztriazole (1.9 grams, 14 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (2.69 grams, 14 mmol) were added to a stirred solution of 2-(4-bromobenzenethio)-1-cyclohexane-1-carboxylate (3.69 grams, 11.6 mmol) in dimethylformamide (50ml) at room temperature. After 30 minutes hydroxylamine hydrochloride (3.25 grams, 47 mmol) and triethylamine (9.7ml, 70 mmol) were added and the mixture was stirred for 12 hours. The solvent was removed and the reaction mixture was extracted from water with ethyl acetate. The organics were concentrated and the crude mixture was purified by silica gel chromatograph (elution with 98% dichloromethane/2% methanol) to provide N-hydroxy-2-(4-bromobenzenethio)cyclohexane-1-carboxamide.

m-Chloroperbenzoic acid (273 mg, 0.8 mmol of 50% pure solid) was added to a stirred solution of N-hydroxy-2-(4-bromobenzenethio)-cyclohexane-1-carboxamide (290 mg, 0.88 mmol) in dichloromethane (5ml) at 0°C. After 2 hours the mixture was diluted with further dichloromethane and washed with brine. The organic layer was dried (sodium sulfate) and concentrated. The crude mixture was purified by silica gel chromatography (elution with 98% dichloromethane/2% methanol) to provide N-hydroxy-2-(4-bromobenzenesulfoxy)-cyclohexane-1-carboxamide. Mass spectrum (thermospray): m/Z 346 (MH⁺). ¹H NMR (CDCl₃, 400 MHz, ppm) δ 10.50 (br s, 1H), 7.70 (d, 2H), 7.55 (d, 2H), 2.95 (m, 1H), 2.80 (m, 1H), 2.20-2.00 (m, 2H), 1.90-1.10 (m, 6H).

50

EXAMPLE 9

N-hydroxy-2-(4-methoxybenzenesulfoxy)-cyclohexane-1-carboxamide

The title compound of Example 9 was prepared by a method analogous to that described in Example 8.


Mass spectrum (thermospray): m/Z 298.0 (MH⁺). ¹H NMR (CDCl₃, 400MHz, ppm) δ 7.60 (d, 2H), 7.10 (d, 2H), 3.90 (s, 3H), 3.00 (m, 1H), 2.90 (m, 1H), 2.25 (m, 1H), 2.10-1.40 (m, 7H).

Claims

1. A compound of the formula

5

10



15 or a pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

n is 0, 1 or 2;


p is 0 or 1;

q is 0, 1 or 2;

20 X, Y and Z are each independently CR¹R² wherein R² and R² are each independently hydrogen, (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)aryltiho, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylarnino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroarylxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; (C₂-C₆)alkenyl, (C₆-C₁₀)aryl(C₂-C₆)alkenyl, (C₅-C₉)heteroaryl(C₂-C₆)alkynyl, (C₂-C₆)alkynyl, (C₆-C₁₀)aryl(C₂-C₆)alkynyl, (C₅-C₉)heteroaryl(C₂-C₆)alkynyl, (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkyl (difluoromethylene), (C₁-C₃)alkyl(difluoromethylene)(C₁-C₃)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)aryltiho, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylarnino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroarylxy, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyl(hydroxymethylene), piperidyl, (C₁-C₆)alkylpiperidyl, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, R³(C₁-C₆)alkyl wherein R³ is (C₁-C₆)acetylpirerazino, (C₆-C₁₀)arylpirerazino, (C₅-C₉)heteroarylpirerazino, (C₁-C₆)alkylpirerazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpirerazino, (C₅-C₉)heteroaryl(C₁-C₆)alkylpirerazino, morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)arylpireridyl(C₁-C₆)alkyl, (C₆-C₁₀)arylpiperidyl(C₁-C₆)alkyl, (C₆-C₁₀)heteroarylpireridyl(C₁-C₆)alkyl, (C₁-C₆)acylpiperidyl, or a group of the formula

40

45




wherein r is 0 to 6:

50 D is hydroxy, (C₁-C₆)alkoxy or NR⁴R⁵ wherein R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)arylpireridyl, (C₅-C₉)heteroarylpireridyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl or (C₃-C₆)cycloalkyl; piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)arylpireridyl, (C₅-C₉)heteroarylpireridyl, (C₁-C₆)acetylpirerazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpirerazino, (C₅-C₉)heteroarylpirerazino, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, R⁶(C₂-C₆)alkyl, (C₁-C₅)alkyl(CHR⁶)(C₁-C₆)alkyl wherein R⁶ is hydroxy, (C₁-C₆)acyloxy, (C₁-C₆)alkoxy, piperazino, (C₁-C₆)acylamino, (C₁-C₆)alkylthio, (C₆-C₁₀)aryltiho, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino, ((C₁-C₆)alkyl)₂amino, (C₁-C₆)acetylpirerazino, (C₁-C₆)alkylpirerazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpirerazino, (C₅-C₉)heteroaryl(C₁-C₆)alkylpirerazino, morpholino, thiomorpholino, piperidino or pyrrolidino; R⁷(C₁-C₆)alkyl, (C₁-C₅)alkyl(CHR⁷)(C₁-C₆)alkyl wherein R⁷ is piperidyl or (C₁-C₆)alkylpiperidyl; and CH

(R⁸)COR⁹ wherein R⁸ is hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₅-C₉)heteroaryl(C₁-C₆)alkyl, (C₁-C₆)alkylthio(C₁-C₆)alkyl, (C₆-C₁₀)arylthio(C₁-C₆)alkyl, (C₁-C₆)alkylsulfinyl(C₁-C₆)alkyl, (C₆-C₁₀)arylsulfinyl(C₁-C₆)alkyl, (C₁-C₆)alkylsulfonyl(C₁-C₆)alkyl, (C₆-C₁₀)arylsulfonyl(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, ((C₁-C₆)alkylamino)₂(C₁-C₆)alkyl, R¹⁰R¹¹NCO(C₁-C₆)alkyl or R¹⁰OCO(C₁-C₆)alkyl wherein R¹⁰ and R¹¹ are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl and (C₅-C₉)heteroaryl(C₁-C₆)alkyl; and R⁹ is R¹²O or R¹²R¹³N wherein R¹² and R¹³ are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl and (C₅-C₉)heteroaryl(C₁-C₆)alkyl; and Ar is (C₆-C₁₀)aryl or (C₅-C₉)heteroaryl, each of which may be optionally substituted by (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl(C₂-C₆)alkenyl, (C₅-C₉)heteroaryl(C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₆-C₁₀)aryl(C₂-C₆)alkynyl or (C₅-C₉)heteroaryl(C₂-C₆)alkynyl optionally substituted by (C₁-C₆)alkyl, (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroarylthio, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino, ((C₁-C₆)alkyl)₂amino or R³alkyl wherein R³ is defined as above; halo, hydroxy, (C₁-C₆)alkyl or (C₁-C₆)alkoxy wherein the alkyl or alkoxy groups may be optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroarylthio, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxyl, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; (C₂-C₆)alkenyl, (C₆-C₁₀)aryl(C₂-C₆)alkenyl, (C₅-C₉)heteroaryl(C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₆-C₁₀)aryl(C₂-C₆)alkynyl, (C₅-C₉)heteroaryl(C₂-C₆)alkynyl, (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₁-C₆)alkyl (difluoromethylene), (C₁-C₃)alkyl(difluoromethylene)(C₁-C₃)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroarylthio, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyl(hydroxymethylene), piperidyl, (C₁-C₆)alkylpiperidyl, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, R³(C₁-C₆)alkyl or R³(C₁-C₆)alkoxy wherein R³ is (C₁-C₆)acylpiperazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpiperazino, (C₅-C₉)heteroaryl(C₁-C₆)alkylpiperazino, (C₁-C₆)alkylpiperazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpiperazino, morpholino, thimorpholino, piperidino, pyrrolidino, piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)aryl(piperidyl, (C₅-C₉)heteroaryl(piperidyl, (C₁-C₆)alkylpiperidyl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(piperidyl(C₁-C₆)alkyl, (C₅-C₉)heteroaryl(piperidyl(C₁-C₆)alkyl, (C₁-C₆)acylpiperidyl, or a group of the formula

35



40

45

wherein r and D are as defined above;

with the proviso that when q is 1 and X and Y are both CR¹R² wherein one of either R¹ or R² must be hydrogen, p must be 1;

with the proviso that when q is 0, the compound of formula I is not bicyclic; and

with the proviso that when the broken line of formula I represents a double bond, R² does not exist

50

2. A compound according to claim 1, wherein q is 0 or 2.
3. A compound according to claim 1, wherein q is 0 or 1.
4. A compound according to claim 1, wherein n is 2
5. A compound according to claim 1, wherein X and Y are both CR¹R² wherein R¹ and R² are hydrogen.

6. A compound according to claim 1, wherein Ar is methoxyphenyl, phenoxyphenyl, benzoxyphenyl or halophenyl.
7. A compound according to claim 1, wherein q is 0, p is 1, m is 2, X and Y are CR¹R² are hydrogen and Ar is methoxyphenyl, phenoxyphenyl or benzoxyphenyl.
- 5 8. A compound according to claim 1, wherein q is 0, p is 0, m is 2, X and Y are CR¹R² are hydrogen and Ar is methoxyphenyl, phenoxyphenyl or benzoxyphenyl.
- 10 9. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments and a pharmaceutically acceptable carrier
- 15 10. A method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
- 20 11. A method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in treating such a condition.

25

30

35

40

45

50

55



(19)

Europäischer Patentamt

Europäischer Patentamt

Officier européen des brevets



(11)

EP 0 818 442 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
30.12.1998 Bulletin 1998/53(51) Int Cl. 6: C07C 317/44, C07C 323/60,
C07D 209/48, C07D 213/64,
A61K 31/16(43) Date of publication A2:
14.01.1998 Bulletin 1998/03

(21) Application number: 97304971.1

(22) Date of filing: 08.07.1997

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

- Rizzi, James P.
Groton, Connecticut 06340 (US)
- Rawson, David J.
Sandwich, Kent (GB)


(30) Priority: 12.07.1996 US 21652 P

(74) Representative: Hayles, James Richard
Pfizer Limited,
Patents Department,
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)(71) Applicant: PFIZER INC.
New York, N.Y. 10017 (US)(72) Inventors:

- Burgess, Laurence E.
Groton, Connecticut 06340 (US)

(54) Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of
tumour necrosis factor

(57) A compound of the formula



wherein n, p, q, X, Y and Ar are as defined herein,
useful in the treatment of arthritis, cancer, tissue ulceration,
restenosis, periodontal disease, epidermolysis
bullosa, scleritis or other diseases characterized by
matrix metalloproteinase activity, as well as AIDS, sepsis,
septic shock or other diseases involving the production
of TNF.

EP 0 818 442 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 97 30 4971
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	WO 95 09841 A (BRITISH BIOTECH PHARMACEUTICALS) 13 April 1995 * page 6 - page 7; claims 1,16 *	1,9	C07C317/44 C07C323/60 C07D209/48 C07D213/64
A	EP 0 606 046 A (CIBA-GEIGY) 13 July 1994 * page 8, line 41 - line 50; claims 1,2 *	1,9	A61K31/16
P, X	EP 0 780 386 A (HOFFMANN-LA ROCHE, ET AL.) 25 June 1997 * page 57, line 58 - line 59; claims 1,30,32 *	1-11	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07C C07D A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claims 10,11 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search THE HAGUE	Date of completion of the search 27 October 1998	Examiner English, R	
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			